← Back to Search

Behavioral Intervention

Electronic Quality of Life Reporting for Post-Pediatric Liver Transplant (SPaRO Trial)

N/A
Waitlist Available
Led By Eyal Shemesh, MD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This trial uses a smartphone application/web interface to collect reports of a pediatric liver transplant recipient's quality of life from the child and parent, in order to evaluate how well the application can help integrate these evaluations into care.

Who is the study for?
This trial is for pediatric liver transplant recipients aged over 8 and under 20 years, who had their transplant at least a year ago. They must speak English or Spanish well enough to understand the study and have internet access. It's not for those planning to change medical services within a year.Check my eligibility
What is being tested?
The study tests how well a smartphone app/web interface can collect quality of life reports from kids with liver transplants and their parents. The goal is to see if these reports can help improve care by using the Pediatric Liver Transplant Quality of Life questionnaire.See study design
What are the potential side effects?
Since this trial involves answering questionnaires through an app or web interface, there are no direct physical side effects like you'd expect with medication. However, participants may experience stress or discomfort while reflecting on their quality of life.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Baseline medication level variability index (MLVI)
Implementation metric
Medication level variability index (MLVI)
+4 more
Other outcome measures
Rejection

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pediatric liver transplant recipientsExperimental Treatment1 Intervention
As this is a single arm trial, all eligible liver transplant recipients and their caregivers will be enrolled in this arm. Eligible participants are children who received a liver transplant at least 1 year prior to enrollment at a participating SNEPT center and continue to receive their post-transplant care at that center.

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiOTHER
871 Previous Clinical Trials
527,070 Total Patients Enrolled
The Hospital for Sick ChildrenOTHER
692 Previous Clinical Trials
6,946,541 Total Patients Enrolled
Emory-Children's CenterOTHER
3 Previous Clinical Trials
5,000,438 Total Patients Enrolled

Media Library

PeLTQL delivery via electronic means (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05241847 — N/A
Quality of Life Clinical Trial 2023: PeLTQL delivery via electronic means Highlights & Side Effects. Trial Name: NCT05241847 — N/A
PeLTQL delivery via electronic means (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05241847 — N/A
Quality of Life Research Study Groups: Pediatric liver transplant recipients
~61 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top